Monday, 31 August 2026European Markets

VERIMATRIX Stock Went Down By Over 20% In The Last 10 Sessions

Loading stream...

(vianews) - shares of verimatrix (cac 40: vmx.pa) fell by a staggering 20.98% in 10 sessions from €0.77 to €0.61 at 13:10 est on thursday, after two sequential sessions in a row of losses. cac 40 is jumping 0.85% to €6,944.48, following the last session's downward trend.

about verimatrix

verimatrix société anonyme provides security solutions that protect digital content, applications, and devices worldwide. the company offers security solutions for various markets, including automotive, sports, financial services, healthcare, internet of things, live sports, media and entertainment, and tv, as well as for content owners. the company was formerly known as inside secure s.a. and changed its name to verimatrix société anonyme in july 2017. verimatrix société anonyme was founded in 1995 and is based in meyreuil, france.

earnings per share

as for profitability, verimatrix has a trailing twelve months eps of €-0.021.

volatility

verimatrix's last week, last month's, and last quarter's current intraday variation average was a negative 13.34%, a negative 1.36%, and a positive 2.52%.

verimatrix's highest amplitude of average volatility was 13.34% (last week), 3.04% (last month), and 2.52% (last quarter).

more news about verimatrix (vmx.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com